Petition to FDA Seeks to Modify Trial Regulations Following Deaths
By Zachary Brennan -
Published 18 May 2017
A petition submitted to the US Food and Drug Administration (FDA) in 2016 has been updated recently, as it seeks to reform FDA requirements for investigational new drug (IND) applications, investigational device exemptions (IDEs) and new drug applications (NDAs).
Categories: News, US, FDA, Biologics and biotechnology, Clinical, Drugs, Postmarket surveillance
Tags: citizen petition, FDA petition, clinical trial regulations